Evolus Inc Stock Buy Hold or Sell Recommendation
| EOLS Stock | USD 16.50 0.01 0.06% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Evolus Inc is 'Strong Hold'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Evolus Inc given historical horizon and risk tolerance towards Evolus. When Macroaxis issues a 'buy' or 'sell' recommendation for Evolus Inc, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Evolus Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Evolus and provide practical buy, sell, or hold advice based on investors' constraints. Evolus Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
Evolus |
Execute Evolus Buy or Sell Advice
The Evolus recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Evolus Inc. Macroaxis does not own or have any residual interests in Evolus Inc or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Evolus' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Hold
Market Performance | Good | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Evolus Trading Alerts and Improvement Suggestions
| Evolus Inc appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 202.09 M. Net Loss for the year was (61.69 M) with profit before overhead, payroll, taxes, and interest of 92.73 M. | |
| Evolus Inc currently holds about 84.48 M in cash with (34.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.51. | |
| Over 82.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from gurufocus.com: TANG CAPITAL MANAGEMENT LLC Acquires New Stake in Kezar Life Sciences Inc |
Evolus Returns Distribution Density
The distribution of Evolus' historical returns is an attempt to chart the uncertainty of Evolus' future price movements. The chart of the probability distribution of Evolus daily returns describes the distribution of returns around its average expected value. We use Evolus Inc price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Evolus returns is essential to provide solid investment advice for Evolus.
| Mean Return | 0.65 | Value At Risk | -3.97 | Potential Upside | 6.26 | Standard Deviation | 3.09 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Evolus historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Evolus Stock Institutional Investors
The Evolus' institutional investors refer to entities that pool money to purchase Evolus' securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | Geode Capital Management, Llc | 2024-06-30 | 1.2 M | Soleus Capital Management, L.p. | 2024-06-30 | 1.2 M | Boothbay Fund Management, Llc | 2024-06-30 | 996.5 K | Schroder Investment Management Group | 2024-06-30 | 977.6 K | Assenagon Asset Management Sa | 2024-06-30 | 947.1 K | Millennium Management Llc | 2024-06-30 | 899.4 K | D. E. Shaw & Co Lp | 2024-06-30 | 871.1 K | Rice Hall James & Associates, Llc | 2024-06-30 | 851.3 K | Soros Fund Management Llc | 2024-06-30 | 850 K | Nantahala Capital Management, Llc | 2024-06-30 | 5.8 M | Perceptive Advisors Llc | 2024-06-30 | 5.8 M |
Evolus Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 16.7M | (7.3M) | 43.7M | (11.7M) | 8.9M | 12.7M | |
| Net Borrowings | 70.7M | 39.5M | (27.6M) | (500K) | (450K) | (427.5K) | |
| Free Cash Flow | (98.0M) | (61.0M) | (34.4M) | (11.7M) | (35.6M) | (37.4M) | |
| Depreciation | 5.0M | 7.7M | 6.3M | 4.5M | 5.9M | 3.7M | |
| Capital Expenditures | 4.6M | 3.1M | 970K | 2.9M | 1.6M | 1.6M | |
| Net Income | (90.0M) | (163.0M) | (46.8M) | (74.4M) | (61.7M) | (64.8M) | |
| Change To Netincome | (990K) | 59.2M | 17.4M | 18.2M | 20.9M | 14.8M | |
| Other Non Cash Items | 18.0M | 51.3M | 9.1M | 84.6M | 11.2M | 10.7M | |
| End Period Cash Flow | 109.9M | 102.6M | 146.3M | 53.9M | 62.8M | 89.4M |
Evolus Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Evolus or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Evolus' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Evolus stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.60 | |
β | Beta against Dow Jones | 0.40 | |
σ | Overall volatility | 3.03 | |
Ir | Information ratio | 0.18 |
Evolus Volatility Alert
Evolus Inc currently demonstrates below-average downside deviation. It has Information Ratio of 0.18 and Jensen Alpha of 0.6. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Evolus' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Evolus' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Evolus Fundamentals Vs Peers
Comparing Evolus' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Evolus' direct or indirect competition across all of the common fundamentals between Evolus and the related equities. This way, we can detect undervalued stocks with similar characteristics as Evolus or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Evolus' fundamental indicators could also be used in its relative valuation, which is a method of valuing Evolus by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Evolus to competition |
| Fundamentals | Evolus | Peer Average |
| Return On Equity | -8.62 | -0.31 |
| Return On Asset | -0.0936 | -0.14 |
| Profit Margin | (0.22) % | (1.27) % |
| Operating Margin | (0.09) % | (5.51) % |
| Current Valuation | 1.07 B | 16.62 B |
| Shares Outstanding | 63.09 M | 571.82 M |
| Shares Owned By Insiders | 12.30 % | 10.09 % |
| Shares Owned By Institutions | 82.21 % | 39.21 % |
| Number Of Shares Shorted | 4.88 M | 4.71 M |
| Price To Earning | (5.55) X | 28.72 X |
| Price To Book | 53.90 X | 9.51 X |
| Price To Sales | 4.39 X | 11.42 X |
| Revenue | 202.09 M | 9.43 B |
| Gross Profit | 92.73 M | 27.38 B |
| EBITDA | (30.24 M) | 3.9 B |
| Net Income | (61.69 M) | 570.98 M |
| Cash And Equivalents | 84.48 M | 2.7 B |
| Cash Per Share | 1.51 X | 5.01 X |
| Total Debt | 126.55 M | 5.32 B |
| Debt To Equity | 1.59 % | 48.70 % |
| Current Ratio | 2.60 X | 2.16 X |
| Book Value Per Share | 0.31 X | 1.93 K |
| Cash Flow From Operations | (34.01 M) | 971.22 M |
| Short Ratio | 8.26 X | 4.00 X |
| Earnings Per Share | (0.90) X | 3.12 X |
| Price To Earnings To Growth | (0.52) X | 4.89 X |
| Target Price | 23.43 | |
| Number Of Employees | 304 | 18.84 K |
| Beta | 1.31 | -0.15 |
| Market Capitalization | 1.04 B | 19.03 B |
| Total Asset | 189 M | 29.47 B |
| Retained Earnings | (558.98 M) | 9.33 B |
| Working Capital | 64.13 M | 1.48 B |
Note: Acquisition by Farrell Peter C of 11789 shares of Evolus at 10.25 subject to Rule 16b-3 [view details]
Evolus Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Evolus . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Evolus Buy or Sell Advice
When is the right time to buy or sell Evolus Inc? Buying financial instruments such as Evolus Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Evolus in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Buywrite ETFs Thematic Idea Now
Buywrite ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Buywrite ETFs theme has 25 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Buywrite ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Evolus Stock Analysis
When running Evolus' price analysis, check to measure Evolus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evolus is operating at the current time. Most of Evolus' value examination focuses on studying past and present price action to predict the probability of Evolus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evolus' price. Additionally, you may evaluate how the addition of Evolus to your portfolios can decrease your overall portfolio volatility.